We are the Pannexin company

This new class of drugs is based on the discovery that Pannexin 1 channels play an important role in the pathophysiology of many diseases.

Pannex Therapeutics Inc. is a preclinical stage biopharmaceutical company, founded with a focus to develop life-transforming therapies, based on blocking Pannexin1 channels.

This new class of drugs is based on the discovery that Pannexin 1 channels play an important role in the pathophysiology of many diseases.

We are the first in transforming this new pharmacological target into a new therapeutic approach for many severe diseases with high unmet medical need. With chronic pain as our first target indication, we will develop a project portfolio covering indications from therapeutic areas like cancer, CNS, inflammatory and many other diseases. Currently we are working on a unique platform of first-in-class, highly effective and specific Pannexin1 channel blockers.

Our team

David Bravo PhD

Chief Executive Officer
Co-founder

David, is the founder of Pannex Therapeutics and has worked, in the area of Pannexin 1 and chronic pain as a target, for many years. He is a successful serial entrepreneur, expert in industrial development, guiding his previous and current companies to transform scientific research into viable products. He successfully raised public funds and private investments for his current and past companies. With 10 years of experience in R&D and management of innovative technological projects in Neuroscience and Neuropharmacology, David has the experience and drive to build a successful company and to transform his initial research on Pannexin 1 and pain into a commercially successful product. David holds a PhD in Neuroscience from the University of Santiago, Chile, was awarded with the National Prize of Innovation in Chile in 2015.

Thomas Gerlach PhD

Chief Strategic Officer
Co-founder

Thomas brings more than 30 years of experience in biopharmaceuticals and venture capital, in a broad range of areas. He has worked in big multinational companies like Knoll and Novartis in Germany and Switzerland, but also in successful startups like Actelion, (Switzerland and Brazil), early startup like Biozeus (Brazil) and in venture capital, focused on biopharmaceuticals, diagnostics and medical equipment. During his career, he worked in drug development, leading global teams, but also in commercial and operational functions, as general manager of Actelion Brazil. During his 9 years in venture capital he identified investment opportunities and supported portfolio companies on operational as well as board level. Thomas holds an PhD in Biology and an BA in chemistry, from the university of Mainz (Germany) and has spent 3 years as researcher at Michigan State University.

Gerhard Gross PhD

Chief Scientific Officer
Co-founder

Gerhard has more than 30 years of experience in drug development, holding senior positions in global pharmaceutical companies in several countries. His specific focus is drug discovery (ADME/PK), screening and profiling lead candidates, and general drug development. He was a key player in the development and registration of numerous drugs during his time at Aventis, Novartis and Lundbeck e.g. Leflunomide, Gliveec, Myfortic, Zoledronate, Zelmac, Everolimus, Pimecrolimus, ERL080, Exjade, Aliskirenn and holds many patents. During his time at Janssen he set up a new strategy for the department of drug developability and introducing the concept of receptor binding kinetics for PK/PD and establishing global in silico ADMET approaches for discovery. Gerhard has a M.Sc. in Physics and Chemistry, a Ph.D. in Organic Chemistry from the University of Marburg, Germany and a postdoc at the university of Utah, USA.

Jordan Marrocco PhD

Jordan brings over 12-years’ experience in neuropharmacology, behavioral investigations, animal models, developmental origins of diseases, genomics, and epigenetics of brain circuits. During his career as a researcher, he developed in vitro and in vivo models to test the efficacy and safety of novel and fast-acting antidepressants and discovered novel biomarkers and molecular mechanisms of chronic diseases including metabolic and mental disorders. He also developed new strategies to discover biomarkers for targeted therapies, individualized medicine, and diagnosis in chronic disorders and collaborated with industry, but also private foundations. Jordan is a molecular neuroscientist, with a Ph.D. from the University of Lille (France) and a postdoc at The Rockefeller University (United States).

Advisory board

Pannex Therapeutics is advised by a vastly experienced board with decades of expertise in their respective academic fields.

Prof. Robert Naviaux

Department of medicine, pediatrics and Pathology World-class researcher in chronic diseases study.

Prof. Rodrigo Noseda

Department of Anesthesia, Critical Care & Pain Medicine 17 years of experience in migraine studies.

Dr. Eduardo Butelman

Laboratory of biology of addictive diseases 25 years of experience in opioid addiction research.

Prof. Luis Constandil

Laboratory of neurobiology of pain 20 years of experience in chronic pain studies.